The dominant reasons, documented across multiple 2025 real-world studies, are: cost and insurance denials (47.6% of discontinuations), intolerance of GI side effects (14.6%), and supply shortages (11.8%)
Villar S, Ciardi M, Morillas-Espaa A, Snchez-Zurano A, Acin-Fernndez G, Lafarga T
Novo Nordisk announced headline results from STEP UP, a phase IIIb trial investigating subcutaneous semaglutide 7.2 mg for obesity Novo Nordisk announced headline results from STEP UP, a phase IIIb trial in the global STEP programme
Because GH supports protein synthesis and tissue repair, these hormonal responses provide a plausible basis for improved muscle fullness and recovery, though direct clinical measurements of body composition or recovery outcomes with ipamorelin in humans are not yet well-established
Introduction When it comes to maintaining our health, the conversation often revolves around the importance of antioxidants